Q-omics provides the consensus-scored C2CD4D profile across patient tissues and cancer cell-line models. C2CD4D expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, C2CD4D is differentially expressed in 12, with the highest sampling consensus in STAD. Additionally, C2CD4D RNA expression shows 14,873 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, STAD, and TGCT as cancer lineages where C2CD4D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD4D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD4D survival associations across molecular data types. C2CD4D RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD4D RNA expression–survival associations across cancer types. High C2CD4D expression shows unfavorable associations in KIRP and LGG, but favorable associations in HNSC, SCLC, LIHC and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for C2CD4D RNA expression.
This table summarizes C2CD4D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for C2CD4D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD4D shows higher tumor expression in STAD, LUAD, COAD, LIHC, BRCA and HNSC. The STAD box plot shows higher C2CD4D RNA expression in tumor versus normal tissue (log2 FC = +1.711, t-test p < 0.001).
This table shows molecular features associated with C2CD4D in patient tissues and cancer cell lines. In patient samples, C2CD4D shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD4D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
